Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Albiges

Showing results (1-10 of 260) with videos related to

Pageof 26
Sort By:
Drugs|June 30, 2011
Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinomaBernard Escudier, Laurence Albiges
Current Opinion in Urology|July 9, 2015
Current and future strategies in nonclear-cell metastatic renal cell carcinomaLaurence Albiges, Bernard Escudier
Bulletin Du Cancer|January 1, 2019
Annalisa Guida, Laurence Albiges
Expert Review of Anticancer Therapy|September 6, 2018
Treating patients with renal cell carcinoma and bone metastasesAnnalisa Guida, Bernard Escudier, Laurence Albiges
Therapeutic Advances in Medical Oncology|March 28, 2020
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinomaElie Rassy, Ronan Flippot, Laurence Albiges
Therapeutic Advances in Medical Oncology|March 28, 2017
Nivolumab in renal cell carcinoma: latest evidence and clinical potentialCamille Mazza, Bernard Escudier, Laurence Albiges
The Oncologist|July 19, 2012
Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?Laurence Albiges, Vincent Molinie, Bernard Escudier
Drugs|September 7, 2018
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell CarcinomaRonan Flippot, Bernard Escudier, Laurence Albiges
Expert Opinion on Emerging Drugs|May 19, 2015
Emerging tyrosine kinase inhibitors for the treatment of renal cancerRoberto Iacovelli, Laurence Albiges, Bernard Escudier
Drugs|April 11, 2013
Optimal management of metastatic renal cell carcinoma: current statusBernard Escudier, Laurence Albiges, Guru Sonpavde
Pageof 26

Showing results (1-10 of 260) with videos related to

Sort By:
Pageof 26
Drugs|June 30, 2011
Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinomaBernard Escudier, Laurence Albiges
Current Opinion in Urology|July 9, 2015
Current and future strategies in nonclear-cell metastatic renal cell carcinomaLaurence Albiges, Bernard Escudier
Bulletin Du Cancer|January 1, 2019
Annalisa Guida, Laurence Albiges
Expert Review of Anticancer Therapy|September 6, 2018
Treating patients with renal cell carcinoma and bone metastasesAnnalisa Guida, Bernard Escudier, Laurence Albiges
Therapeutic Advances in Medical Oncology|March 28, 2020
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinomaElie Rassy, Ronan Flippot, Laurence Albiges
Therapeutic Advances in Medical Oncology|March 28, 2017
Nivolumab in renal cell carcinoma: latest evidence and clinical potentialCamille Mazza, Bernard Escudier, Laurence Albiges
The Oncologist|July 19, 2012
Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?Laurence Albiges, Vincent Molinie, Bernard Escudier
Drugs|September 7, 2018
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell CarcinomaRonan Flippot, Bernard Escudier, Laurence Albiges
Expert Opinion on Emerging Drugs|May 19, 2015
Emerging tyrosine kinase inhibitors for the treatment of renal cancerRoberto Iacovelli, Laurence Albiges, Bernard Escudier
Drugs|April 11, 2013
Optimal management of metastatic renal cell carcinoma: current statusBernard Escudier, Laurence Albiges, Guru Sonpavde
Pageof 26